Timothy Eisen

University of Pavia

Papers

1

Total Citations

2,259

H-Index

1

About

Timothy Eisen is a leading oncologist whose work has fundamentally shaped the management of renal cell carcinoma (RCC). His primary research focuses on the clinical development of targeted therapies and immunotherapies for kidney cancer, with a particular emphasis on translating molecular insights into practical, evidence-based treatment guidelines. Eisen’s most influential contribution is his authorship of the ESMO Clinical Practice Guidelines for RCC, a seminal paper cited over 2,250 times that has served as the global standard for diagnosis, treatment, and follow-up. Beyond this landmark work, he has been instrumental in pivotal clinical trials evaluating tyrosine kinase inhibitors and checkpoint inhibitors, helping to establish combination therapies as the backbone of advanced RCC care. His research has directly improved survival outcomes and quality of life for thousands of patients. Eisen’s ability to synthesize complex trial data into actionable clinical pathways has made him a trusted voice in oncology. For students and researchers, his career exemplifies how rigorous clinical investigation can drive real-world change, setting the benchmark for evidence-based practice in genitourinary cancers.

Research Focus

Key Achievements

1
H-Index
1
Papers
2,259
Total Citations
2,259
Avg Citations/Paper
🏆 Most Cited Paper
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2,259 citations · 2014
📈 Most Prolific Year: 2014 (1 Papers)
🤝 Key Collaborators: 7
🏛 Institutions: University of Pavia

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 10 days ago